FindTrial
Sign In

Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Mellitus

Correlation Between Serum Adiponectin and Resistin Levels and Degree of Hepatic Fibrosis In Metabolic Dysfunction _Associated Steatotic Liver Disease (MASLD)With Type2 Diabetes Mellitus

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06715189
Enrollment
80
Registered
2024-12-04
Start date
2024-12-01
Completion date
2025-12-30
Last updated
2024-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Fibrosis

Brief summary

Metabolic dysfunction asociated steatotic liver disease prevalence is 25%world wide diabetic patients have a risk for MASLD then have hepatic fibrosis so we study correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic fibrosis In Metabolic dysfunction asociated steatotic liver disease in patients with type2 Diabetes Mellitus

Interventions

DIAGNOSTIC_TESTserum Adiponectine and Resistin

corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis

DIAGNOSTIC_TESTfibroscan

hepatic fibrosis detection in type 2 diabetes mellutis

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* patients of both sex who have type2 Diabetes Mellitus for less than five years

Exclusion criteria

alcholics ,chronic liver disease elevated liver functions , sever infection \-

Design outcomes

Primary

MeasureTime frameDescription
degree of hepatic fibrosis in MASLD with type 2 diabetes mellitus1 yearadiponectineand resistine level with degree of hepatic fibrosis in MASLD pt. with type 2 DM

Contacts

Primary ContactELZAHRAA K Mohammed, spcialist
elzahraaadbelrehem@sohag.edu.eg01064954825
Backup Contactusama M Abdelaal, professor
01065962094

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026